Clinics, Genetics and Treatment in a Russian Cohort of Young Patients with Xeroderma Pigmentosum: A Single Center Experience
Authors:
- Tatiana BelyshevaTBTatiana Belysheva
- Tatiana NasedkinaTNTatiana Nasedkina
- Ekaterina ZelenovaEZEkaterina Zelenova
- Vera SemenovaVSVera Semenova
- Peter SparberPSPeter Sparber
- Elena SharapovaESElena Sharapova
- Denis SofronovDSDenis Sofronov
- Fatima MakhachevaFMFatima Makhacheva
- Kamilla GadzhimuradovaKGKamilla Gadzhimuradova
- Marina DorofeevaMDMarina Dorofeeva
- Olga BozhkoOBOlga Bozhko
- Yana VishnevskayaYVYana Vishnevskaya
Preprint
- 27 August 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Xeroderma pigmentosum (XP) and Cockayne syndrome (CS) are rare autosomal recessive DNA repair disorders. XP is characterized by extreme sensitivity to UV-radiation and a very high risk of skin cancer. To date, little is known about the clinical characteristics and genetic basis of these diseases in Russia. Here, we present a detailed study of 14 patients (aged 5–30 years) from 11 unrelated families of diverse ethnic backgrounds. Using a multigene panel or whole-genome sequencing, we identified homozygous or compound heterozygous variants in XPC (8 patients) and XPA (3 patients). In one family with two XP cases, a patient with CS and compound heterozygous ERCC6 variants was identified. In total, 110 family members were screened to determine their carrier status. Skin cancer was revealed in 12/13 (92%) of XP patients, with a median age at diagnosis of 12.5 years (range 5–22). Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma developed in 10, 6, and 3 patients, respectively. All three cancer types occurred in 2 patients. All patients underwent surgical treatment; additionally, two patients with BCC received targeted therapy (vismodegib, sonidegib). Anti-PD-1 immunotherapy was administered with a favorable clinical response in three patients with advanced SCC or melanoma.Keywords
All Related Versions
This publication has 66 references indexed in Scilit:
- Efficacy of immune checkpoint inhibitors in patients with xeroderma pigmentosum and advanced cutaneous squamous-cell carcinoma and literature reviewAnnales de Dermatologie et de Vénéréologie, 2026
- Treatment With Sonidegib for Multiple Basal Cell Carcinomas in a Patient With Xeroderma PigmentosumActas Dermo-Sifiliograficas, 2026
- Rare internal malignancies in xeroderma pigmentosum: A report of two cases from Tunisia and analysis of driver mutationsCancer Pathogenesis and Therapy, 2026
- Prevention of Skin Cancers With Topical Calcipotriol and Fluorouracil in Patients With Xeroderma PigmentosumJAMA Dermatology, 2023
- Thyroid nodules in xeroderma pigmentosum patients: a feature of premature agingJournal of Endocrinological Investigation, 2020
- Molecular analysis directs the prognosis, management and treatment of patients with xeroderma pigmentosumDNA Repair, 2020
- Cockayne syndrome: Clinical features, model systems and pathwaysAgeing Research Reviews, 2017
- A new XPC gene splicing mutation has lead to the highest worldwide prevalence of xeroderma pigmentosum in black Mahori patientsDNA Repair, 2011
- Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophyDNA Repair, 2008
- Identification of splicing mutations of the last nucleotides of exons, a nonsense mutation, and a missense mutation of the XPAC gene as causes of group A xeroderma pigmentosumMutation Research/DNA Repair, 1992